A descriptive comparison of phase 3 results and head-to-head trials in inflammatory bowel diseases

Significant heterogeneity in trial design, populations, and outcome reporting limits the predictive value of placebo-controlled trials. Randomized head-to-head trials remain essential for optimizing IBD therapeutic strategies.